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Abstract
Introduction Oncoplastic breast surgery (OBS) has developed as an extension of breast-conserving surgery (BCS) in an 
effort to improve esthetic and functional outcome following surgery for breast cancer. The aim of the present study was to 
evaluate the possible benefits of OBS, as compared with BCS, with regard to health-related quality of life (HRQoL), using 
patient-reported outcome measures (PROMs).
Patients and methods Patients treated with OBS (n = 200) and BCS (n = 1304) in the period 1 January 2008 to 31 December 
2013 were identified in a research database and in the Danish Breast Cancer Cooperative Group (DBCG) registry. Data on 
patient, tumor, and treatment characteristics were retrieved from the DBCG registry. Patients were sent a survey including the 
Breast-Q™ BCT postoperative module and a study-specific questionnaire (SSQ) in 2016. A good outcome in the Breast-Q 
module was defined as above the median. OBS was compared to BCS using a logistic regression analysis, and then adjusted 
for potential confounders, yielding odds ratios (OR) with 95% confidence intervals.
Results There was a statistically significant better outcome considering the HRQoL domain “Psychosocial Well-being “ for 
patients treated with OBS as compared with BCS (OR 2.15: 1.25–3.69). No statistically significant differences were found 
for the domains “Physical Well-being” (0.83: 0.50–1.39), “Satisfaction with Breast” (0.95: 0.57–1.59), or “Sexual Well-
being” (1.42: 0.78–2.58).
Conclusion The present study indicates better outcomes of HRQoL for breast cancer patients treated with OBS as compared 
to patients treated with BCS. There was no increase in physical discomfort among OBS patients despite more extensive 
surgery.
Keywords Oncoplastic breast surgery · Breast conserving surgery · Patient-reported outcome · Breast-Q · Breast cancer
Introduction
Breast-conserving surgery (BCS) followed by adjuvant radi-
otherapy, is documented to be equal to mastectomy with 
regard to oncological outcomes [1–3], and has to a large 
extent replaced total mastectomy in the last few decades. 
Oncoplastic breast surgery (OBS) was developed with the 
aim of further improving the esthetic and functional out-
comes of BCS [4–7], as these affect health-related quality of 
life (HRQoL). However, only a few studies have addressed 
patient-reported outcomes (PROs), e.g., physical and psy-
chosocial well-being, following OBS or among patients 
treated with conventional BCS [8, 9].
Several studies have evaluated oncoplastic surgery as a 
concept [4, 5, 7, 10], others have considered surgical tech-
niques [4, 10], postoperative complications [6, 10, 11], as 
well as oncological [6, 11, 12] and esthetical outcomes [6, 
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11, 13–15]. With the development of the Breast-Q™ [16, 
17] and recently the Breast-Q™ BCT module, a validated 
instrument for patient-reported outcome measures (PROMs) 
is now available.
OBS can be defined as level I and level II surgical tech-
niques [7, 18] and OBS can be considered as an extension of 
conventional BCS [10]. By applying OBS in BCS, a larger 
number of patients may achieve good esthetic and functional 
outcomes, and some may also escape mastectomy [6, 7, 11, 
19, 20].
The aim of this study was to investigate whether OBS 
improves HRQoL in patients undergoing BCS. For this pur-
pose, we used the Breast-Q™ BCT module.
Materials and methods
Patients
Patients treated for invasive primary breast cancer in the 
period 1 January 2008 to 31 December 2013 were recruited 
from two cohorts. Patients in the OBS cohort (n = 236) 
were mainly recruited from the Southern Region of Den-
mark, while patients in the control cohort, the BCS cohort 
(n = 1423), were recruited from the Northern Region of Den-
mark. Clinical data were collected from the Danish Breast 
Cancer Cooperative Group registry (DBCG registry) [21] 
and the Danish Cause of Death Registry (DAR) [22]. In 
2016, patients were sent a survey including the Breast-Q™ 
BCT postoperative module and a study-specific question-
naire (SSQ).
Oncoplastic breast surgery cohort
Patients treated with OBS were consecutively registered in 
the research database at the Hospital of Southwest Jutland, 
which is approved by the Danish Data Protection Agency 
[23], and 236 patients were registered (Fig. 1). Of these, 17 
patients were not registered in the research database with 
primary invasive breast cancer and 6 cases were double 
entries to the database. According to data from the Danish 
Cause of Death Registry (DAR) [22] 13 patients had died at 
the time of the survey. In all, 200 patients remained in the 
OBS cohort at the time of the survey.
Patients in the OBS cohort were treated with either 
level I or II oncoplastic surgery [7, 18]. In this study, we 
define level I OBS as the adaptation of glandular tissue 
with minor mobilization of glandular tissue with or with-
out repositioning of the NAC, and Level II OBS as reduc-
tion (therapeutic) mammoplasty, volume displacement and 
volume replacement techniques. The latter include recon-
structions with perforator-based flaps [24, 25] and mus-
cle sparing latissimus dorsi flaps [26]. Furthermore, the 
majority of the patients treated with level II surgery, i.e., 
patients who had a therapeutic mammoplasty or recon-
struction using displacement techniques, had simultaneous 
contralateral surgery to achieve symmetry. Patients oper-
ated with mastectomy followed by an immediate autolo-
gous or implant reconstruction were not included in this 
study.
Breast‑conserving surgery cohort
All patients diagnosed with primary invasive breast can-
cer treated with BCS in the Region of Northern Denmark 
from 1 January 2008 to 31 December 2013 were identified 
as a consecutive population-based cohort in the national 
DBCG registry [21] (n = 1423) (Fig. 1). Data from the 
Danish Cause of Death Registry (DAR) [22] showed that 
119 patients had died at the time of the survey, and in all, 
1304 patients remained in the BCS cohort. OBS was not 
implemented in the Northern Region of Denmark as a rou-
tine surgical procedure during the study period.
Patient survey
The survey included the Breast-Q™ BCT postoperative 
module and a study-specific questionnaire (SSQ). The 
SSQ included the completion of an informed consent and 
selected patient characteristics. Patients included in the 
remaining OBS and the BCS cohorts were sent the sur-
vey (n = 1504). A digital letter was posted to the patients 
in March 2016 from the Hospital of Southwest Jutland 
by E-post with information on the research project and a 
digital link to the survey (n = 1229). E-post is a Danish 
web-application developed for secure digital communica-
tion between citizens, companies and public authorities 
i.e., the health care system. E-post is compulsory in Den-
mark for all citizens, although some citizens are allowed 
to have only a postal address, e.g., due to lack of computer 
skills. A reminder was sent after four weeks to patients 
who had not answered. Patients who were not available by 
E-post were simultaneously mailed a letter with the same 
survey in paper form to their postal address (n = 275). 
No reminder was sent in their cases. Data were collected 
using the Research Electronic Data Capture (REDCap) 
[27] database, designed for this study. Access to REDCap 
[27] was licensed by the Odense Patient data Explorative 
Network (OPEN) University of Southern Denmark [28]. 
Surveys returned in paper form were transferred to the 
REDCap [27] database.
Fig. 1  Breast-Conserving Surgery (BCS) and Oncoplastic Breast Sur-
gery (OBS) cohorts
◂
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Study population
In all, 764 patients replied the survey. Based on a second 
DBCG registry dataset form, 2017 patients were excluded 
if they at the time of the survey had had recurrence of the 
disease, a secondary mastectomy were registered with bilat-
eral cancer, did not have surgery in the period 2008 to 2013 
or if the patients were not registered in the DBCG registry 
(Fig. 1).
In the BCS and the OBS cohorts there were 631 and 96 
evaluable replies, respectively. The total response rate for 
evaluable replies was 48.3% (727/1504), while the response 
rates for the BCS and OBS cohorts were 48.4% (631/1304) 
and 48.0% (96/200), respectively.
Patients in the BCS cohort underwent surgery in the 
Northern region of Denmark. Patients in the OBS cohort 
underwent surgery in the Region of Southern Denmark 
at the Hospital of Southwest Jutland, Esbjerg, (1 January 
2008–31 December 2013; n = 40), at the Hospital of South 
Jutland, Aabenraa (1 October 2010–31 December 2013; 
n = 48), or at Privathospitalet Hamlet, Copenhagen (1 Janu-
ary 2008–31 December 2010; n = 8). Among patients in the 
OBS cohort, 32 had level I surgery. Sixty-four patients had 
level II surgery and 32 of them had contralateral surgery for 
symmetry. The mean follow-up time among all 727 patients 
was 60.8 months (range 26–100).
Danish breast cancer cooperative group registry
The national clinical database, the DBCG registry [21], 
includes data from all departments of radiology, breast 
surgery, pathology and oncology in Denmark involved in 
the diagnosis and treatment of breast cancer. Data include 
information on patient age, type of breast cancer diagnosis, 
time of diagnosis, tumor characteristics, surgical treatment, 
oncological adjuvant therapy and information on recurrent 
disease and death. The use of oncoplastic surgical techniques 
has been registered since 1 July 2010. With the permission 
of the Danish Clinical Registries [29], the Danish National 
Board of Health [29], data for patients in the OBS cohort 
and the BCS cohort, were identified in the DBCG registry 
[21]. The present study used data for the patients until 3 
January 2017. We used one data set retrieved in 2014 and 
one retrieved in 2017. Data from 2014 were used to iden-
tify patients in the BCS cohort in the DBCG registry [21] 
with primary breast cancer. Data from 2017 were used to 
exclude replies from patients who at the time of the survey 
had had a recurrent disease, bilateral cancer, a mastectomy, 
did not have surgery in the period 2008 to 2013 or were not 
registered in the DBCG registry. Data on patient, tumor, and 
treatment characteristics were also retrieved from the DBCG 
registry from 2017.
Patient‑reported Outcome Measure (PROM)—the 
Breast‑Q™
The Breast-Q™ is a disease-specific validated questionnaire 
for evaluating PRO [16]. The linguistically validated Dan-
ish version of the Breast-Q™ BCT postoperative module 
includes 10 domains. In the present study, we selected the 
domains with regard to the patient-reported outcome of 
treatment, namely “Satisfaction with breast”, “Psychoso-
cial Well-being”, “Sexual Well-being” and “Physical Well-
being”. Permission to use the Danish version of the ques-
tionnaire was granted by the MAPI Research Trust Institute 
[30] which administers the Breast-Q™. Breast-Q™ data are 
transformed into scores ranging from 0 to 100 according 
to the guidelines for the Breast-Q postoperative module. 
Higher scores represent more favorable outcomes.
Characteristics of patients, tumors, and treatments
Several factors may affect the patient-reported outcome. In 
the present analysis, we used the a priori selected patient 
characteristics: age at surgery, follow-up time, menopausal 
status, chest measurement, bra cup-size, BMI, smoking hab-
its, as well as marital status, education and living arrange-
ment. Furthermore, the following tumor and treatment char-
acteristics were selected: TNM-classification, lumpectomy 
size, tumor location, radiotherapy, chemotherapy, endocrine 
therapy and immunotherapy, and axillary surgery. These 
data were mainly collected from the DBCG registry [21] 
whereas complementary data were collected from the SSQ.
Statistical methods
The OBS and BCS cohorts were compared using univariate 
logistic regression analyses for the scores for each domain 
in the Breast-Q BCT module. The analyses were conducted 
separately for the OBS cohort including level I and II onco-
plastic procedures and for the OBS cohort only including 
level II procedures. The scores in the Breast-Q domains 
(0–100) for the BCS cohort were transformed from a linear 
variable into a binary variable by the median score used for 
the cut-off value for each domain as the dependent variable, 
i.e., scores lower than the median score were considered less 
favorable and higher scores as more favorable. The risk of 
a better outcome was compared between the OBS and BCS 
cohorts as the logistic regression analysis yielded odds ratios 
(OR) with 95% confidence intervals. Factors that might 
affect the patient-reported outcome, i.e., patient, tumor and 
treatment characteristics, were selected à priori and included 
in a second multivariate logistic regression model. We per-
formed sensitivity analyses excluding patients registered in 
the DBCG registry as treated with OBS from 1 July 2010 
to 31 December 2013 in the BCS cohort (n = 24). We also 
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compared responders (n = 727) to non-responders (n = 683) 
in order to check for potential selection bias. This analysis 
included age at surgery and the same tumor characteristics 
and treatment factors as used in the analyses of responding 
patients. Data were analyzed using IBM–SPSS Statistics 
version 24.0, IBM Corp., US.
Ethics
The study was approved by The Regional Committee on 
Health Research Ethics for Southern Denmark. The study 
was submitted for evaluation to The Regional Ethical 
Review Board in Lund, Sweden, as the research was con-
ducted at Lund University, Sweden, but their approval was 
not required (Dnr.2014/882). The research database identify-
ing OBS patients was approved by the Danish Data Protec-
tion Agency [23].
Results
Patient, tumor, and treatment factors
Compared with the BCS cohort, patients in the OBS cohort 
were younger, more often never-smokers or non-smokers 
at the time of surgery, and had a lower BMI (Table 1). 
Notably, they had larger tumors, larger lumpectomies, were 
more often treated with chemotherapy, endocrine therapy 
and axillary clearance, and nearly all had been treated with 
radiotherapy (Table 2). This indicates that the patients in 
the OBS cohort had more advanced cancers than those in 
the BCS cohort.
Psychosocial well‑being
The median score for the domain “Psychosocial Well-being” 
was 82 with a response rate of 99.3%. There was a better 
outcome for the OBS cohort (OR 2.15: 1.25–3.69) (Table 3). 
When comparing the OBS cohort including only level II 
oncoplastic surgery with the BCS cohort, we found a differ-
ence that was even stronger (OR 2.67: 1.37–5.20).
Physical well‑being
The median score for “Physical Well-being” was 78 with a 
response rate of 98.7%. There was no statistically significant 
difference between OBS and BCS patients as the OR was 
0.83 (0.50–1.39) (Table 3). When only level II surgery was 
included in OBS, the OR was even closer to 1.00 (0.94: 
0.50–1.74).
Satisfaction with breast
The median score for the domain “Satisfaction with Breast” 
was 74 with a response rate of 99.2%. The adjusted OR 
showed no statistically significant difference between the 
Table 1  Patient characteristics
*Column percent does not always add up to 100% as missing data are 
only shown if > 5%
Covariates Category BCS OBS Total
n = 631 n = 96 n = 727
Column percent*
Age at surgery (year)  < 50 15.5 25.0 16.8
 ≥ 50 to < 65 56.6 52.1 56.0
 ≥ 65 27.9 22.9 27.2
Menopause Premenopausal 23.6 34.4 25.0
Postmenopausal 73.9 63.5 72.5
Bra size A 8.7 13.5 9.4
B 31.2 26.0 30.5
C 26.1 24.0 25.9
D 18.5 16.7 18.3
E 4.1 6.3 4.4
 ≥ F 5.1 8.3 5.5
Missing 6.2 5.2 6.1
Chest measurement 
(cm)
 ≤ 82 20.9 21.9 21.0
83–87 20.0 25.0 20.6
88–92 13.8 15.6 14.0
93–97 8.4 7.3 8.3
 ≥ 98 15.1 10.4 14.4
Missing 21.9 19.8 21.6
BMI  < 25 36.8 41.7 37.4
25.0–29.9 35.3 39.6 35.9
 ≥ 30 17.6 16.7 17.5
Missing 10.3 2.1 9.2
Ever smoker Non-smoker 40.6 57.3 42.8
Smoker 53.3 42.7 53.6
Smoking at surgery Non-smoker 77.7 86.5 78.8
Smoker 19.5 13.5 18.7
Marital status Single 7.9 11.5 8.4
Married 68.3 69.8 68.5
Separated 0.6 1.0 0.7
Divorced 9.2 10.4 9.4
Widow 13.3 7.3 12.5
Living arrangement Living alone 23.6 18.8 23.0
Cohabiting 69.6 77.1 70.6
Others 3.2 1.0 2.9
Educational level (year) Primary school 20.8 12.5 20.6
Secondary school 10.0 12.5 10.3
Short (2) 32.3 22.9 31.1
Medium (3–4) 31.9 37.5 32.6
Higher (3–6) 4.3 7.3 4.7
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OBS cohort and the BSC cohort (Table 3). This was also 
true when only level II OBS patients were considered.
Sexual Well‑being
The median score for the domain “Sexual Well-being” was 
58 with a response rate of only 69.6%. There was no statisti-
cally significant difference between OBS and BCS (Table 3). 
Including only level II surgery indicated a slightly better out-
come in the OBS group, although not statistically significant 
(OR 1.86: 0.90–3.83).
Sensitivity analysis and analysis comparing 
responders with non‑responders
Sensitivity analysis excluding patients from the BCS cohort 
who were registered in the DBCG registry as treated with 
OBS in the period 1 July 2010 to 31 December 2013 (n = 24), 
showed all the same results (data not shown). Responders 
and non-responders were very similar with regard to age, 
tumor characteristics and treatment factors (Table 4).
Discussion
In this study, we evaluated the outcome of OBS compared 
with BCS using the Breast-Q™ BCT postoperative mod-
ule. We found that patients treated with OBS had a bet-
ter “Psychosocial Well-being “. However, no significant 
differences were found for the domains “Physical Well-
being”, “Satisfaction with Breast” or “Sexual Well-being”.
Evaluation of surgical treatment of breast cancer by 
oncological outcomes remains essential. However, the 
quality of the health care services provided also needs 
attention. There is now an increasing demand to evaluate 
how patients perceive the results of treatment, i.e., PRO 
[8, 9, 19]. In this study we took advantage of Breast-Q™ 
which can be used as a standardized and validated instru-
ment for evaluation of HRQoL in patients operated for 
breast cancer [16, 31–33].
Although the esthetic and functional outcome of OBS 
compared with BCT has been investigated before [15], there 
have been few studies comparing HRQoL between OBS and 
BCS so far. The Breast-Q™ BCT pre- and postoperative 
module was introduced in 2015. One year later, O´Connell 
et al. [8] published their initial experience with the full BCT 
postoperative module including 200 patients, thus establish-
ing a benchmark for future research. However, few studies 
have addressed the HRQoL outcome of BCS [8, 9, 16] and 
OBS [34] or both. Compared with previous studies, patients 
included in the OBS cohort in this study represent the full 
spectrum of OBS, i.e., level I and II surgery, and the sample 
is therefore not restricted to one surgical procedure such as 
the therapeutic mammoplasty technique [34].
In the domain “Psychosocial Well-being” we found a 
median score of 82, similar to the results of O´Connell [8] 
and Dahlbäck [35], using Breast-Q™ for evaluation of the 
outcome of BCT, while Langendiik [36] found a mean score 
at 70.1 and Vesprini [9] found a mean score at 73.5. In our 
study we found a statistically significant better outcome for 
the OBS cohort, including level I and II surgery, compared 
with the BCS cohort. The difference was strengthened by 
including only level II surgery from the OBS cohort.
In their analyses of the domain “Physical Well-being” 
after BCT with Breast-Q™, Langendjik [36] and Vesprini 
[9] found mean scores of 71.2 and 74, respectively. A 
slightly higher score of 75 was reported by O`Connell 
[8]. The median score of 78 in this study reflects a low 
grade of physical discomfort and there was no statistically 
significant difference between OBS and BCT. One could 
have expected a lower score for the OBS cohort, particu-
larly in cases of level II surgery as this surgery is more 
extensive and often involves the contralateral breast. On 
the contrary, there was a slight difference in the figures, 
indicating better outcomes for OBS compared with BCS.
Table 2  Tumor characteristics and treatment factors
*Column percent does not always add up to 100 as missing data are 
not shown
Covariates Category BCS OBS Total
n = 631 n = 96 n = 727
Column percent*
Tumor size T1 ≤ 20 mm 84.0 62.5 81.2
T2 21–50 mm 15.7 34.4 18.2
T3 ≥ 50 mm 0.3 0.0 0.3
Lumpectomy size 
 (cm3)
 < 50 20.0 15.6 19.4
50–99 30.7 26.0 30.1
100–199 33.0 32.3 32.9
 ≥ 200 14.9 21.9 15.8
Tumor location Upper lateral 37.9 40.6 38.2
Upper medial 14.6 8.3 13.8
Lower lateral 8.9 9.4 8.9
Lower medial 7.0 6.3 6.9
Central 6.2 15.6 7.4
Overlapping regions 23.8 19.8 23.2
Axillary dissection No 66.2 52.1 64.4
Yes 33.8 44.8 35.2
Radiotherapy No 4.4 2.1 4.1
Yes 95.6 97.9 95.9
Chemotherapy No 58.6 49.0 57.4
Yes 41.4 51.0 42.6
Endocrine therapy No 42.3 34.4 41.3
Yes 57.7 65.6 58.7
Immune therapy No 91.1 89.6 90.9
Yes 8.9 10.4 9.1
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In the analysis of the domain “Satisfaction with Breast” 
Vesprini [9] and Langendjik [36] found mean scores of 59.3 
and 65.7, respectively, while Dahlbäck [35] and O´Connell 
[8] found median scores of 66 and 68, respectively. Hence, 
our median score of 74 in the present study means our scores 
are higher than those reported previously and they indicate 
a higher degree of satisfaction with the breast. High scores 
generally imply that possible differences are difficult to 
detect and, consequently, we found no difference between 
OBS and BCS. However, when only level II surgery was 
considered, a tendency toward a better outcome in the OBS 
group was noted.
The domain “Sexual Well-being” had a markedly lower 
median score of 58 and, furthermore, the response rate was 
low at 69.6%. This pattern has also been seen in previous 
studies investigating BCT [8, 9, 36], and it seems to be a 
general issue for this domain. Therefore, results must be 
interpreted with caution. We found no difference between 
OBS and BCS. However, when only level II surgery was 
considered, a slight tendency toward a better outcome in the 
OBS group was noted.
In summary, the results show that patients treated with 
OBS reported statistically better psychosocial health than 
those treated with BCS. Patients treated with OBS also 
scored slightly higher for the domains “Satisfaction with 
breasts” and “Sexual Well-being” particularly when the 
analyses only included level II OBS, although the differ-
ence was not statistically significant. Notably, the results 
in the domain “Physical Well-being” showed no significant 
differences despite the fact that patients treated with OBS 
had more extensive and often bilateral surgery.
A methodological issue to be considered is the definition 
of OBS. In studies published in the last few decades, the def-
inition of OBS has varied, making it difficult to compare the 
outcome results from different studies. In the present study, 
we have based our definition on that proposed by Clough 
et al. [7], which is widely accepted. In the publication by 
Chatterjee et al. [18], a consensus definition and classifica-
tions system, developed by the American Society of Breast 
Surgeons, was presented which was strongly influenced by 
Clough’s definition [7]. By using a widely accepted defini-
tion of OBS we hope that the results from the present study 
can be used for comparison with future studies.
Another methodological issue to be considered is the 
PROM instrument chosen. The Breast-Q™ BCT module is 
now widely accepted as a valuable PROM instrument for 
breast-conserving surgery [31, 32 37], which is why we have 
chosen the Breast-Q™ BCT postoperative module.
Furthermore, the validity of the data used must be con-
sidered. Data in the research database were only used for 
identification of patients treated with OBS. To avoid mis-
classification of patient, tumor and treatment characteristics, 
all data for both the OBS and the BCS cohorts were obtained 
from the national DBCG registry [21]. In a recent study by 
Cronin-Fenton et al., [38] the authors conclude that DBCG 
data are valid for epidemiological studies of breast cancer 
treatment; thus, we believe that the validity of the data is 
good.
Table 3  Odds ratios for and adjusted odds ratios for scores in Breast-Q modules “Psychosocial Well-being”, “Physical Well-being”, “Sexual 
Well-being”, and “Satisfaction with Breasts” for BSC and OBS level I + II and BCS and OBS level II
a Adjusted for age, follow-up time, menopausal status, T-classification, lumpectomy size, tumor location, bra size, chest measurement, BMI, 
radiotherapy, chemotherapy, endocrine therapy, immunotherapy, axillary clearance, smoking, marital status, living arrangement and education
Domain Cohort All Below median Above median OR ORa
Psychosocial Well-being BCS 627 311 316 1.00 1.00
Median = 82 OBS level I + II 95 38 57 1.48 (0.95–2.29) 2.15 (1.25–3.69)
BCS 627 311 316 1.00 1.00
OBS level II 63 23 40 1.71 (1.00–2.96) 2.67 (1.37–5.20)
Physical Well-being BCS 623 277 346 1.00 1.00
Median = 78 OBS level I + II 95 50 45 0.72 (0.47–1.11) 0.83 (0.50–1.39)
BCS 623 277 346 1.00 1.00
OBS level II 63 32 31 0.78 (0.46–1.30) 0.94 (0.50–1.74)
Satisfaction with Breast BCS 626 308 318 1.00 1.00
Median = 74 OBS level I + II 95 48 47 0.94 (0.61–1.45) 0.95 (0.57–1.59)
BCS 626 308 318 1.00 1.00
OBS level II 63 29 34 1.13 (0.67–1.90) 1.25 (0.67–2.33)
Sexual Well-being BCS 431 205 226 1.00 1.00
Median = 58 OBS level I + II 75 33 42 1.15 (0.71–1.89) 1.42 (0.78–2.58)
BCS 431 205 226 1.00 1.00
OBS level II 50 21 29 1.25 (0.69–2.27) 1.86 (0.90–3.83)
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To avoid confounding by indication, the patients in the 
OBS and BCS cohorts were recruited from different geo-
graphical regions. The unselected demographic BCS cohort 
thus also possibly included some more advanced cases that 
might have been selected for OBS. In the early study period, 
such cases were not identified, but from 1 July 2010, 24 
cases could be identified in the DBCG registry. Sensitivity 
analyses excluding these patients did not alter the results. 
The OBS cohort may include patients with relatively more 
advanced disease, i.e., the OBS cohort could include patients 
with tumor and treatment characteristics known to predict 
less satisfying outcomes of HRQoL. By adjusting for these 
variables in the statistical analyses, we have reduced this 
potential selection bias.
Response rates in other surveys are reported to be between 
31% [9] and 76% [35]. With a total response rate in our study 
of 48.3% for evaluable replies (OBS cohort 48.4%, BCS cohort 
48.0%) we find our response rate acceptable. The analysis 
comparing patients in the responder and the non-responder 
cohorts showed only minor differences, that is, the responder 
cohort is considered representative of the survey cohort, show-
ing no selection bias.
Table 4  Patient and tumor 
characteristics and treatment 
factors for the responder and 
non-responder cohorts
*Column percent does not always add up to 100 as missing data are not shown. Patients in the Responder 
cohort (n = 764) and Non-responder cohort (n = 1504–764 = 740) were excluded (Responder cohort (n = 37) 
and Non-responder cohort (n = 57)) if the patients were not registered in the DBCG registry, did not have 
surgery in the study period, did not have breast cancer, had bilateral cancers or a secondary breast cancer 
(bilateral event) or if they had a recurrent disease or had undergone a mastectomy before the survey (Fig. 1)
Covariates Category OBS BCS
Responders Non-responders Responders Non-responders
n = 96 n = 71 n = 631 n = 612
Column percent*
Age at surgery (years)  < 50 25.0 18.3 15.5 12.7
 ≥ 50 to < 65 52.1 52.1 56.6 50.0
 ≥ 65 22.9 29.6 27.9 37.3
Tumor size T1 ≤ 20 mm 62.5 63.4 84.0 82.2
T2 21 – 50 mm 34.4 33.8 15.7 17.3
T3 ≥ 50 mm 0.0 0.0 0.3 0.3
Lumpectomy size  (cm3)  < 50 15.6 12.7 20.0 20.9
50–99 26.0 32.4 30.7 27.8
100–199 32.3 26.8 33.0 30.9
 ≥ 200 21.9 25.4 14.9 17.5
Tumor location Upper lateral 40.6 32.4 37.9 41.0
Upper medial 8.3 12.7 14.6 11.4
Lower lateral 9.4 11.3 8.9 10.8
Lower medial 6.3 12.7 7.0 6.2
Central 15.6 7.0 6.2 5.4
 > 1 region 19.8 22.5 23.8 22.1
Axillary dissection No 52.1 59.2 66.2 64.1
Yes 44.8 39.4 33.8 35.8
Radiotherapy No 2.1 5.6 4.4 4.2
Yes 97.9 94.4 95.6 95.8
Chemotherapy No 49.0 56.3 58.6 69.4
Yes 51.0 43.1 41.4 30.6
Endocrine therapy No 34.4 35.2 42.3 40.8
Yes 65.6 64.8 57.7 59.2
Immune therapy No 89.6 90.1 91.1 94.3
Yes 10.4 9.9 8.9 5.7
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Conclusion
The present study indicates better outcomes of HRQoL for 
breast cancer patients treated with OBS as compared to patients 
treated with BCS. There was no increase in physical discom-
fort among OBS patients despite more extensive surgery.
Acknowledgements Open access funding provided by Lund Univer-
sity. This study was financially supported by The Malmö University 
Hospital Cancer Research Fund, The Einar and Inga Nilsson Founda-
tion, Skåne University Hospital Funds and Donations and The Hospi-
tal of Southwest Jutland. The authors wish to express their gratitude 
to DBCG and especially Maj-Britt Jensen. The authors also wish to 
express their gratitude to OPEN, University of Southern Denmark. The 
funding sponsors had no influence on the study design, analyses of the 
data or the presentation.
Funding This study was financially supported by The Malmö Univer-
sity Hospital Cancer Research Fund, The Einar and Inga Nilsson Foun-
dation, Region Skåne, Skåne University Hospital Funds and Donations, 
and The Hospital of Southwest Jutland. The funding sponsors had no 
influence on the study design, analyses of the data or the presentation.
Compliance with ethical standards 
Conflicts of interest The authors declare that they have no conflicts 
of interest.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual 
participants included in the study.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Wolmark N et al (2002) Twenty-year follow-up of a randomized 
trial comparing total mastectomy, lumpectomy, and lumpectomy 
plus irradiation for the treatment of invasive breast cancer. N 
Engl J Med 347:1233–1241
 2. Blichert-Toft M et al (2008) Long-term results of breast con-
serving surgery vs. mastectomy for early stage invasive breast 
cancer: 20-Year follow-up of the Danish randomized DBCG-
82TM protocol. Acta Oncol 47:672–681
 3. Christiansen P et al (2017) Breast conserving surgery versus 
mastectomy: overall and relative survival—a population based 
study by the Danish Breast Cancer Cooperative Group (DBCG 
) Supplementary material. Acta Oncol 57:1–3
 4. Weber WP et al (2017) Standardization of oncoplastic breast 
conserving surgery. Eur J Surg Oncol 43:1236–1243
 5. Berry MG, Fitoussi AD, Curnier A, Couturaud B, Salmon RJ 
(2010) Oncoplastic breast surgery: a review and systematic 
approach. J Plast Reconstr Aesth Surg 63:1233–1243
 6. Campbel EJ, Romics L (2017) Oncological safety and cosmetic 
outcomes in oncoplastic breast conservation surgery, a review of 
the best level of evidence literature. Breast Cancer 9:521–530
 7. Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM 
(2010) Improving breast cancer surgery: a classification and 
quadrant per quadrant atlas for oncoplastic surgery. Ann Surg 
Oncol 17:1375–1391
 8. O’Connell RL et al (2016) Initial experience of the BREAST-
Q breast-conserving therapy module. Breast Cancer Res Treat 
160:79–89
 9. Vesprini D et al (2017) Patient-reported outcomes following 
breast conservation therapy and barriers to referral for partial 
breast reconstruction. Plast Reconstr Surg 141:1–9
 10. Rose M, Manjer J, Ringberg A, Svensson H (2014) Surgical 
strategy, methods of reconstruction, surgical margins and post-
operative complications in oncoplastic breast surgery. Eur J 
Plast Surg 37:205–214
 11. Losken A, Dugal CS, Styblo TM, Carlson GW (2014) A meta-
analysis comparing breast conservation therapy alone to the 
oncoplastic technique. Ann Plast Surg 72:145–149
 12. Wang K, Huang Y-J, Zhang L-L, Chen J-Y, Yang C-Q (2018) 
Comparison of oncoplastic breast-conserving surgery and 
breast-conserving surgery alone: a meta-analysis. J Breast Can-
cer 21:321
 13. Spautz C et al (2014) Long-term comparison of aesthetical out-
comes after oncoplastic surgery and lumpectomy in breast cancer 
patients. Ann Surg Oncol 22:2500–2508
 14. Massa M, Meszaros P, Baldelli I, Bisso N, Franchelli S (2015) 
Aesthetic evaluation in oncoplastic and conservative breast sur-
gery: a comparative analysis. J Plast Reconstr Surg 3:e339
 15. Ojala K, Meretoja TJ, Leidenius MHK (2017) Aesthetic and 
functional outcome after breast conserving surgery—comparison 
between conventional and oncoplastic resection. Eur J Surg Oncol 
43:658–664
 16. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano 
SJ (2009) Development of a new patient-reported outcome meas-
ure for breast surgery: The BREAST-Q. Plast Reconstr Surg 
124:345–353
 17. Fuzesi S, Cano SJ, Klassen AF, Atisha D, Pusic AL (2017) Vali-
dation of the electronic version of the BREAST-Q in the army of 
women study. Breast 33:44–49
 18. Chatterjee A et al (2019) A consensus definition and classification 
system of oncoplastic surgery developed by the american society 
of breast surgeons. Ann Surg Oncol 26:3436–3444
 19. Paramanathan N et al (2017) Patient-reported outcomes are better 
after oncoplastic breast conservation than after mastectomy and 
autologous reconstruction. Plast Reconstr Surg 5:e1419
 20. Di Micco R et al (2017) Bilateral mammoplasty for cancer: surgi-
cal, oncological and patient-reported outcomes. Eur J Surg Oncol 
43:68–75
 21. DBCG, Danish Breast Cancer Cooperative Group. https ://www.
dbcg.dk/.
 22. Sundhedsdatastyrelsen, Danish Cause of Death Register. https ://
sundh edsda tasty relse n.dk/da.
 23. Datatilsynet, Danish Data Protection Agency. https ://www.datat 
ilsyn et.dk/.
256 Breast Cancer Research and Treatment (2020) 180:247–256
1 3
 24. McCulley SJ, Schaverien MV, Tan VKM, Macmillan RD (2015) 
Lateral thoracic artery perforator (LTAP) flap in partial breast 
reconstruction. J Plast Reconstr Aesthetic Surg 68:686–691
 25. Rose M, Svensson H (2012) Tunnelled lateral fasciocutaneous 
thoracodorsal flap with a skin island in breast reconstruction in 
oncoplastic breast surgery. J Plast Surg Hand Surg 46:404–409
 26. Saint-Cyr M et al (2009) The pedicled descending branch mus-
cle-sparing latissimus dorsi flap for breast reconstruction. Plast 
Reconstr Surg. https ://doi.org/10.1097/PRS.0b013 e3181 93483 8
 27. REDCap. https ://proje ctred cap.org/
 28. OPEN—Syddansk Universitet. https ://www.sdu.dk/da/Om_SDU/
Insti tutte r_centr e/Klini sk_insti tut/Forsk ning/Forsk nings enhed er/
open.aspx
 29. The Danish Clinical Registries, Danish National Board of Health. 
https ://www.rkkp.dk/
 30. Mapi research trust. http://mapi-trust .org/
 31. Liu LQ, Branford OA, Mehigan S (2018) BREAST-Q measure-
ment of the patient perspective in oncoplastic breast surgery. Plast 
Reconstr Surg 6:e1904
 32. Cohen WA et al (2016) The BREAST-Q in surgical research: a 
review of the literature 2009–2015. J Plast Reconstr Aesth Surg 
69:149–162
 33. Stolpner I et  al (2019) Clinical validation of the BREAST-
Q Breast-conserving therapy module. Ann Surg Oncol 
26:2759–2767
 34. Acea-Nebril B et al (2017) The role of oncoplastic breast reduc-
tion in the conservative management of breast cancer: complica-
tions, survival, and quality of life. J Surg Oncol 115:679–686
 35. Dahlbäck C, Ullmark JH, Rehn M, Ringberg A, Manjer J (2017) 
Aesthetic result after breast-conserving therapy is associated with 
quality of life several years after treatment. Swedish women evalu-
ated with BCCT.core and BREAST-Q™. Breast Cancer Res Treat 
164:679–687
 36. Lagendijk M et al (2018) Patient-reported outcome measures may 
add value in breast cancer surgery. Ann Surg Oncol 25:3563–3571
 37. Morley R, Leech T (2019) Optimal assessment tools in assessing 
breast surgery: patient reported outcome measures (PROMs) vs 
objective measures. Gland Surg 8:1–9
 38. Cronin-Fenton DP et al (2017) Validity of Danish Breast Cancer 
Group (DBCG) registry data used in the predictors of breast can-
cer recurrence (ProBeCaRe) premenopausal breast cancer cohort 
study. Acta Oncol 56:1155–1160
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
